[Clinical evaluation of budesonide forte action in patients with atopic bronchial asthma].
An effect of a 6-week therapy with Budesonide forte aerosol Polfa on the course of bronchial asthma has been investigated in 30 atopic asthmatics with double-blind trial. The drug has been administrated in the dose of 200 micrograms four times daily and the results have been compared with placebo and foreign made analogue. Twelve patients required chronic administration of oral glucocorticosteroids in the daily dose of 9.2 mg of prednisone. Dyspnoea, cough, doses of bronchodilators and oral corticosteroids, pulmonary function and bronchial reactivity to histamine have been considered in the clinical analysis. A decrease in the severity of dyspnoea and in the doses of used bronchodilators as well as intensity of cough have been observed during the treatment with inhaled steroids. The mean daily dose of prednisone has decreased to 5.8 mg and oral corticosteroids could be withdrawn in 4 of the patients treated chronically with these drugs. Budesonide forte significantly reduced bronchoconstriction and bronchial reactivity to histamine, compared with baseline values.
Górski
P
P
Kliniki Chorób Zawodowych Instytutu Medycyny Pracy, Lodzi.
Pałczyński
C
C
D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects; D019819:Budesonide; D002908:Chronic Disease; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011282:Pregnenediones / Q000008:administration & dosage* / Q000009:adverse effects
D001993:Bronchodilator Agents; D011282:Pregnenediones; D019819:Budesonide